BCL2 and B-cell chronic lymphocytic leukemia: Another study performing targeted scDNA-seq in CLL patients showed that the use of single-targeting agents, such as BTK inhibitors and BCL2 inhibitors, could give rise to a state of mutual exclusivity among resistance-associated genes in subclones of CLL patients [119].